DYAIDyadic International, Inc.
0.6900USD-6.62%Mkt Cap: 27.64M $P/E: —3d ago
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Produ…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Dyadic International (DYAI) Q2 2026 Earnings Call Transcript Company advances commercialization with initial product shipments and distribution deals. | ||
 Dyadic International, Inc. Q2 2026 Earnings Call Summary Moby summary of Dyadic International, Inc.'s Q2 2026 earnings call | ||
Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... Despite a 52% revenue increase and significant productivity gains, Dyadic International Inc (DYAI) faces a going concern uncertainty, requiring additional capital within the next 12 months. | ||